Chronic Hepatitis C virus (HCV) affects an estimated 3.5 million Americans, making it the most common blood-borne disease in the U.S. Left untreated, HCV can result in chronic liver disease, liver failure, liver cancer or even death. New drugs can cure HCV in upwards of 90 percent of patients, but the treatment comes with a huge price tag: the initial launch price was nearly $100,000 for a 12-week course. Recognizing these challenges, clinical and health plan leaders at Geisinger Health Plan created a robust protocol for the diagnosis and treatment of HCV.
This creation of some site content was partially funded through a Patient Centered Outcomes Research Institute® (PCORI®) Eugene Washington PCORI Engagement Award (4109-ACHPF).
The views presented in this content are solely the responsibility of ACHP and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee.